There are currently 1299 clinical trials in Cleveland, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cleveland Clinic, Cleveland Clinic Foundation, Case Western Reserve University and University Hospitals Cleveland Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Struvite Stones Antibiotic Study
NCT02375295
Recruiting
The aim of this research is to determine an effective antibiotic regimen following definitive surgical therapy of kidney stones caused by bacterial infection (struvite stones).
Gender:
All
Ages:
19 years and above
Trial Updated:
05/16/2022
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Kidney Stones
Register for Updates
Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy
NCT04310241
Recruiting
Amblyopia and strabismus are characterized by a reduction in visual acuity, contrast sensitivity, grating acuity, vernier acuity, reading difficulties and binocular visual function deficits. Treated patients have residual visual function deficits. The purpose of the current study is to quantify various visual functions in amblyopic and strabismic participants at baseline, during and at the completion of treatment.
Gender:
All
Ages:
Between 6 months and 90 years
Trial Updated:
05/06/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Amblyopia, Strabismus
Register for Updates
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
NCT04485260
Recruiting
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose (RP2D) of KRT 232 in combination with ruxolitinib.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/05/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Myelofibrosis
Register for Updates
A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
NCT04492488
Recruiting
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/04/2022
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
Conditions: Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
Register for Updates
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
NCT04543994
Recruiting
The purpose of this study is to determine the safety and efficacy of using remestemcel-L, an ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product (MSCs) delivered by targeted endoscopic delivery to treat people for medically refractory ulcerative colitis. This study will enroll adult patients with medically refractory ulcerative colitis who are planning to switch biologic therapy or undergo colectomy as the next stage in their treatment plan.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Ulcerative Colitis
Register for Updates
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis
NCT04548583
Recruiting
Crohn's disease has several phenotypes (inflammatory, stricturing, fistulizing) and location (small bowel, ileocecal, colon, and perianal). Approximately one third of patients have inflammation limited to the colon. Up to two thirds will become medically refractory and require a total abdominal colectomy for symptom control. The purpose of this study is to determine the safety and efficacy of using allogeneic bone marrow derived mesenchymal stem cells (MSCs) delivered by targeted endoscopic deli... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Crohn Colitis
Register for Updates
Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease
NCT04519697
Recruiting
Approximately 10% of all female Crohn's patients have a rectovaginal fistula. Rectovaginal fistulas cause air, stool, and/or drainage per vagina and may be associated with pain, recurrent urinary tract infections and diminished quality of life. Conventional therapy includes immunosuppressive medications used to treat Crohn's disease and various surgical interventions. However, all have limited ability to heal these fistulas. The purpose of this study is to determine the safety and efficacy of us... Read More
Gender:
Female
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Rectovaginal Fistula, Crohn Disease, Crohn Disease of Vulva, Rectolabial; Fistula
Register for Updates
Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease
NCT05075811
Recruiting
The purpose of this study is to determine the safety and feasibility of using Ossium vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC) to treat people with an ileal pouch anal anastomosis (IPAA) who develop a fistula in the setting of Crohn's disease of the pouch.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Pouch, Ileal, Fistula
Register for Updates
Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease
NCT04519684
Recruiting
Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is the procedure of choice for patients with ulcerative colitis, familial adenomatous polyposis, and select patients with Crohn's disease due to overall low patient morbidity and good quality of life. However, some patients can develop Crohn's disease of the pouch, a clinical diagnosis of Crohn's disease following IPAA. One of the manifestations of Crohn's disease of the pouch includes a fistula from the pouch that travels to t... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Ileal Pouch, Crohn Disease
Register for Updates
Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease
NCT04519671
Recruiting
The purpose of this study is to determine the safety and efficacy of using adult allogeneic bone marrow derived mesenchymal stem cells (MSCs), to treat people for medically refractory perianal fistulizing Crohn's disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Perianal Crohn Disease, Perianal Fistula, Crohn Disease
Register for Updates
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
NCT04578392
Recruiting
Study description - Patients will be randomized according to post-operative recurrence risk to either a high ligation of ileocolic artery or mesenteric sparing ileocolic resection for terminal ileal Crohn's disease. The primary endpoint 6-month endoscopic recurrence. Endpoints - Primary endpoint; 6 months Secondary endpoints at 1 and 5 years post ileocecal resection Study population - Adult Crohn's disease patients with medically refractory terminal ileal Crohn's disease undergoing a primary i... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Crohn Disease
Register for Updates
Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease
NCT04791878
Recruiting
This study plans to enroll 10 patients aged 13-17 years of age with refractory perianal fistulizing disease. Patients will be treated by direct injection to the fistula tract(s) with 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
04/01/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Perianal Fistula Due to Crohn's Disease (Disorder)
Register for Updates